

PeptiDream announces strategic partnership with drug-delivery expert PharmalN

06 June 2019 | News

The partnership enables PeptiDream to use PharmalN's PGC™ technology across its discovery programs to formulate applicable therapeutic peptides with PGC™ and evaluate in vivo the drug carrier/delivery benefits



PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, on 5 June 2019, announced a strategic partnership with Seattle-based PharmalN Corporation for the purpose of investigating the use of PharmalN's proprietary drug carrier and delivery Protected Graft Co-Polymer (PGC™) technology in combination with PeptiDream's peptide discovery and development programs.

PharmalN's breakthrough PGCTM technology is a PEG-based excipient that reversibly binds the therapeutic peptide and unlike PEGylation or other peptide PK extending technologies, does not require the peptide to be modified in any way, thereby fully preserving the potency, function, and mobility of the therapeutic peptide payload. Additionally, the PGCTM technology offers a number of other potentially significant advantages in that it can improve the solubility of the peptide payload, protects the peptide payload from degradation, thereby increasing stability, and acts to slowly releases the peptide payload resulting in a significantly longer circulation half-life. The PGCTM technology has also shown to passively target the peptide payload to tumour sites/ sites of inflammation/infection and can significantly decrease the risk of injection site reactions common to conventional injectables.

Under the partnership, PeptiDream will have the ability to broadly use PharmalN's PGC™ technology across its discovery programs to formulate applicable therapeutic peptides with PGC™ and evaluate in vivo the drug carrier/delivery benefits. Clinical development and commercialization of any peptide employing PharmalN's PGC™ technology would require a specific development and commercialization license.

Patrick Reid, CEO, PeptiDream, said: "PharmalN has developed a very unique and attractive drug carrier/delivery technology that doesn't require modification of the therapeutic peptide payload and could add significant formulation, administration, and deliver benefits to both our internal and external therapeutic programs in which the intended administration route is an injectable. We greatly look forward to working with PharmalN and being able to evaluate the PGCTM technology in such programs."